Results 1 to 10 of about 7,838 (234)

Efficacy and safety of ultra-rapid lispro insulin in managing type-1 and type-2 diabetes: A systematic review and meta-analysis

Indian Journal of Endocrinology and Metabolism, 2023
Background: Mechanistically, subcutaneous ultra-rapid lispro (URLi) is faster than lispro. Whether this translates into a better post-prandial glucose (PPG) and glycemic control in type-1 diabetes (T1DM) and type-2 diabetes (T2DM) is unclear.
Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma   +3 more
doaj   +2 more sources

Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. [PDF]

Diabetes Care
OBJECTIVE To compare the glycemic response and pharmacokinetics (PK) of ultra-rapid lispro (URLi) versus lispro during manual basal rate reductions (BRRs) before exercise with conventional continuous subcutaneous insulin infusion (CSII) in active adults ...
Leohr JK, Abitbol A, Turner LV, Smith LaBell E, Ghosh A, Coutant DE, Riddell MC.   +6 more
europepmc   +2 more sources

Long‐term field study of lispro and neutral protamine Hagedorn insulins treatment in dogs with diabetes mellitus

Veterinary Medicine and Science, 2023
Background The long‐term clinical and biofhemical effects of basal‐bolus insulin treatment with lispro and NPH in dogs with diabetes mellitus are undocumented.
Sharon Kuzi, Michal Mazaki‐Tovi, Shai Hershkovitz, Einat Yas, Rebecka S. Hess   +4 more
doaj   +2 more sources

Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro

Journal of Diabetes Investigation, 2022
Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections.
Takahiro Ishii, Akihiro Katayama, Mihiro Sue, Remi Kuribayashi, Masafumi Tenta, Yuichi Matsushita, Masaya Takeda, Izumi Iseda, Satomi Tani, Kazuyuki Hida   +9 more
doaj   +2 more sources

Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System

Diabetes Technology and Therapeutics, 2021
Background: Automated insulin delivery systems are associated with improved glycemic outcomes for patients with diabetes. Ultrarapid lispro (URLi), which has an accelerated pharmacokinetic profile and shows superior postprandial glucose control compared ...
Debra Ignaut, Richard M Bergenstal
exaly   +2 more sources

Media optimization for SHuffle T7 Escherichia coli expressing SUMO-Lispro proinsulin by response surface methodology

BMC Biotechnology, 2022
Background SHuffle is a suitable Escherichia coli (E. coli) strain for high yield cytoplasmic soluble expression of disulfide-bonded proteins such as Insulin due to its oxidative cytoplasmic condition and the ability to correct the arrangement of ...
Aida Bakhshi Khalilvand, Saeed Aminzadeh, Mohammad Hossein Sanati, Fereidoun Mahboudi   +3 more
doaj   +2 more sources

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

Diabetes Care, 2020
OBJECTIVE To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in patients with type 2 diabetes on a basal-bolus insulin regimen. RESEARCH DESIGN AND METHODS This was a phase 3, treat-to-target, double-blind 26-week study. After
Juan Frias, Annette M Chang, Thomas Blevins   +2 more
exaly   +2 more sources

Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial

Science Bulletin, 2022
Ultra rapid lispro (URLi) is a novel formulation of insulin lispro designed to more closely match the physiological insulin response to a meal, with the aim of improving postprandial glucose (PPG) control.
Weiping Jia
exaly   +2 more sources

Fully closed-loop control with ultra-rapid versus standard insulin lispro: A randomised crossover study simulating missed meal boluses. [PDF]

Diabet Med
Ultra‐rapid insulin lispro (URIL) is associated with faster insulin absorption and earlier offset than standard insulin lispro (IL). This study evaluated whether URIL improves glucose control in a fully closed‐loop setting over an 8‐h period compared to ...
Thabit H, Lim J, Willinska ME, Fullwood C, Hovorka R, Leelarathna L.   +5 more
europepmc   +2 more sources

Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes

Journal of Diabetes Investigation, 2020
Aims/Introduction Ultra‐rapid lispro (URLi) is a novel ultra‐rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog®) in Japanese patients with type 1 diabetes ...
Masanari Shiramoto, Risa Nasu, Tomonori Oura, Makoto Imori, Kenji Ohwaki   +4 more
doaj   +2 more sources